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Patients with psychotic major depression suﬀer prolonged duration and greater severity of illness, including an increased
likelihood of recurrent episodes and resistance to conventional pharmacotherapies. They do not respond to placebo and respond
poorly to antidepressant or antipsychotic monotherapy. On the other hand, as has been demonstrated, they do respond well to
antidepressant and antipsychotic combination therapies. Diﬀerent combinations of drugs were studied, but little is known up
to now with regard to the combination of venlafaxine and olanzapine. The following paper presents three separate case studies
of female patients suﬀering from psychotic unipolar major depression, all of whom were admitted to a psychiatric ward and
successfully treated with a combination of venlafaxine and olanzapine.
1.Introduction
Psychotic major depression aﬀects approximately 20% of
patients hospitalised for major depressive disorder [1, 2]a n d
although it is predominantly higher in elderly patients it has
also been known to aﬀect young people [3].
Patients with psychotic major depression suﬀer pro-
longed duration and greater severity of illness [2, 4], as has
been conﬁrmed by their higher total scores on the Hamilton
Rating Scale for Depression (HAM-D), and in particular
their depressive symptoms scores [5]. They have a shorter
symptom-free interval, an increased likelihood of recurrent
episodes, are at a higher risk of suicide, and show resistance
to conventional pharmacotherapies [2].
Compared with nonpsychotic major depression, patients
with psychotic major depression do not respond to placebo
and respond poorly to antidepressants or antipsychotics
alone. On the other hand, as has been demonstrated, they
do respond well to the combination of antidepressants and
antipsychotics [6].
This combination is, at the moment, the strongest rec-
ommendationregardingpsychoticmajordepressionpatients
by the American Psychiatric Association Practice Guidelines
[7].
Early studies of the eﬀectiveness of this combination
of antidepressants and antipsychotics were related to the
combination of tricyclic antidepressants and conventional
antipsychotics. Despite the positive results obtained, the use
of these molecules has been reduced due to an undesirable
high rate of adverse eﬀects [8, 9].
Recent data suggests that the combination of SSRI anti-
depressants and atypical antipsychotics could prove as eﬀec-
tive as the combination of tricyclic antidepressants and con-
ventional neuroleptics [2, 6, 10].
Among atypical antipsychotic drugs olanzapine is the
most studied in cases of major depression with psychotic
symptoms. Results show eﬃcacy in such cases, suggesting
that olanzapine may have antidepressant properties [11–13].
With regard to new generation antidepressants, the
majority of studies undertaken have focused on SSRIs,
particularly ﬂuoxetine [2].
We are not aware of any current study which has pre-
viously considered the combination of olanzapine and ven-
lafaxine where psychotic depression is concerned.2 Case Reports in Medicine
The existing case reports regarding the aforementioned
combination are, to our knowledge, speciﬁcally aimed at the
treatment of treatment-resistant depression [13, 14].
It has been suggested that randomised double-blind
trials are “almost impossible” when evaluating treatment for
psychotic major depression due to diﬃculty in obtaining
informed consent [4]. Such trials are no longer ethically
justiﬁed due to a patient’s high risk of suicide; therefore,
studying the eﬀects of combining new drugs in single
patients may prove useful.
As a result we have chosen to present three case reports
involving patients suﬀering from psychotic unipolar major
depression, all of whom were admitted into a women’s
psychiatric ward and all of whom were successfully treated
with a combination of venlafaxine and olanzapine.
Case A. M r s .Ai s6 5y e a r so l d ,s u ﬀering recurrent major
depression, which began 10 years ago following her retire-
ment, and which has since led to repeated hospitalisations in
a psychiatric clinic as a result of severe depressive episodes
with melancholic psychotic symptoms.
The patient has followed diﬀerent psychopharmacolog-
ical treatments, with the prescription of SSRIs and typical
neuroleptics, which, over time, have resulted in an onset of
extrapiramidal iatrogenic symptoms, at present unresolved.
The current hospitalisation was determined by a depres-
sive episode which was characterised by depressed mood,
psychomotor retardation, complete loss of autonomy, and
recurrent thoughts of suicide. Delusions including perse-
cution and inappropriate guilt were also present as well as
auditory and visual hallucinations.
At admission, the patient had a HAM-D score of 30 and
presented cognitive impairment and slowdown. An MMSE
was administrated, with a score of 29.
Routine blood tests, including thyroid tests, did not show
any relevant change and the patient’s ECG was normal.
The patient was aﬀected by essential hypertension which
was being controlled with tiazidic diuretics. Results from a
cerebral TC scan were negative.
During the initial phase of the patient’s two-month
treatment, she received a daily dose of diazepam (8mg),
clomipramine (maximum dose of 250mg) and haloperidol
(6mg). There was no positive response shown to this initial
phaseoftreatment,ratherthepatientworsenedtoacomplete
psychomotorarrestwhichinturnledtoenteralnutritionand
urinary catheterisation.
After one-month a new daily treatment was, there-
fore, administered, this consisted of intravenous lorazepam
(8mg), and venlafaxine (150mg) in association with olanza-
pine (10mg).
After10daysthepatienthadbeguntoshowherﬁrstsigns
of a progressive improvement, returning to feed herself and
carrying out bodily functions independently.
After four weeks of the patient’s second phase of trea-
tmentherHAM-Dscalescorewentdownto7andthepatient
was discharged.
The combination of venlafaxine and olanzapine (which
was maintained following the patient’s discharge) was well
tolerated, with the exception of nausea during the ﬁrst three
days of treatment which spontaneously disappeared. No
changes in the patient’s blood pressure were noted.
The patient was discharged from this particular period
of hospitalisation two years ago. Since that discharge she
has had only one other brief admission on account of a
voluntary suspension of therapy. She continues to maintain
a satisfactory clinical balance at follow-up assessments.
Case B. Mrs. B is a 72 years old, admitted for the ﬁrst time
in her life at a psychiatric division. The patient’s symptoms
included depressed mood, insomnia, anhedonia, fatigue,
decreased appetite (with weight loss) and heightened obses-
sive traits.
The most troubling symptom for the patient was the
occurrence of simple auditory hallucinations, such as unde-
ﬁned, though alarming, noises. Delusional ideas of ruin and
feelings of helplessness were also present.
The initial diﬀerential diagnosis at the clinical exam had
to take into account the possibility of an onset of dementia,
despite the absence of memory or orientation disorders,
as the patient had no prior history of mood disorders.
However, the results of a cerebral TC scan (with contrast
enhancement) showed no sign of cerebral atrophy nor any
signiﬁcant vascular lesions. The patient’s MMSE and HAM-
Ds c o r e sw e r er e p o r t e da s2 5a n d2 0 ,r e s p e c t i v e l y .
The HAM-D showed the highest scores for items such
as weight loss, anxiety/somatisation, motor retardation and
sleep disturbances.
Routine blood tests were within range, including thyroid
function.
The diagnosis was a severe depressive episode with
mood-congruent psychotic features.
Wedecidedtoadministeradailytreatmentofvenlafaxine
(150mg) and olanzapine (5mg). We also chose to include a
daily dose of mirtazapine (15mg) in order to improve the
patient’s loss of appetite, and delorazepam (0.5mg) to treat
her insomnia.
Within the ﬁrst days of hospitalisation the patient’s psy-
chotic symptoms had disappeared alongside her insomnia.
The patient’s mood showed some improvement following
the second week of treatment, allowing for the patient’s
discharge after only 16 days.
One month after discharge the patient’s follow-up
assessment showed a HAM-D score of 10. This included
a 50% decrease in all areas with the exception of anxi-
ety/somatisation for which there was a minimal decrease.
The patient’s MMSE score was 28.
Case C. Mrs. C is a 59 years old, who has had several admis-
sions to hospital for recurrent major depression disorder.
After a long period of hospitalisation in a diﬀerent
psychiatric division, the patient was discharged with medical
therapy consisting of high doses of sertraline (300mg per
day), alprazolam (2mg per day), trazodone (75mg per day)
and ﬂurazepam (30mg per day). After only seven days the
patient was again admitted to hospital for attempted suicide
(lacerated veins) this time to our psychiatric clinic. The
motivation for the suicide attempt was a reported worsening
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hallucinations, both of which were noted for the ﬁrst time
in the patient’s medical history.
A year before hospitalisation in question, the patient
had suﬀered a cerebral stroke and was therefore following a
prescribed treatment of anticoagulants and statins. She was
also aﬀected by mild vascular hypertension which, in turn,
was being treated with ACE inhibitors.
The results of the patient’s neurological clinical exam
showed a mild strength deﬁcit at upper and lower left limbs,
resulting from the cerebral stroke. The patient’s cerebral TC
scan was negative, as were her routine blood tests.
The patient’s HAM-D score was 28, with higher scores
relatedtoanxiety/somatisation,cognitivedisordersandsleep
disorders items.
This particular episode for which the patient was admit-
ted was treated as a new psychotic major depressive episode;
however, we considered the possibility that the prescribed
high dosage of sertraline may have induced the patient’s
psychotic symptoms (although rare, psychotic symptoms
through SSRI therapy have been documented) [15, 16].
During the ﬁrst seven days of hospitalisation we reduced,
and then interrupted, the patient’s intake of sertraline and
trazodone. These were substituted with venlafaxine (225mg
per day) and olanzapine (5mg per day) together with
alprazolam (2mg per day) and ﬂurazepam (30mg per day),
with which the patient was already being treated.
Due to the fact that the patient had previously suﬀered
a cerebral stroke the patient provided us with her informed
consent in order to allow us to administer olanzapine.
The patient showed a prompt remission of symptoms
and was subsequently discharged after 18 days.
The patient’s HAM-D score at discharge was 8, showing
a reduction of over 75% in all areas.
At the patient’s one-month follow-up assessment a good
clinical balance was being maintained and there were no
signs of side eﬀects caused by the drugs administered. As a
precaution, the dosage of olanzapine was gradually reduced
and ﬁnally suspended two-months after discharge, whereas
the treatment with venlafaxine continues to the present
day.
2. Discussion
These three case reports seem to demonstrate the positive
eﬀects of a venlafaxine and olanzapine combination in the
treatment of psychotic major depression.
What is of particular relevance is the promptness of
clinical response; two of the patients in our case studies
beingdischargedinjustoverafortnightandthethirdpatient
responding to the combination after one-month.
This promptness is particularly interesting, when taking
into consideration the symptoms of psychotic major depres-
sion which include greater severity, greater incapacitation
and prolonged periods of illness when compared to nonpsy-
chotic major depression.
The eﬃcacy of remission was similar in all three cases:
both with the patients suﬀering recurrent depression, who
had previously undergone several other treatments in their
medicalhistory,aswiththepatientsuﬀeringherﬁrstepisode.
Furthermore all cases presented showed a good response
to medium-low dosage (from 150mg to 225mg per day
of venlafaxine and 5mg to 10mg per day of olanzapine).
This might also explain the almost complete absence of side
eﬀects.
In particular the medium-low dosage of venlafaxine
administered to the two patients (A and C) aﬀected by
hypertensionhadnoinﬂuenceontheirrespectiveparameters
(an increase in blood pressure being a dose-related eﬀect of
venlafaxine).
Bearing in mind the study carried out by Zanardi et
al. [17], which considers venlafaxine 300mg per day an
eﬀective treatment for psychotic depression, we suggest that
a combination with olanzapine may result in a useful option
for those patients suﬀering psychotic major depression and
hypertension.
With regard to the duration of treatment, it is not
yet clear how long the antidepressant and antipsychotic
association should last [3].
The fact that the patient described in Case A relapsed
after an episode of nonadherence to therapy, two years after
her initial discharge seems to indicate, in accordance with
recent literature [18], the need for long-term treatment
where antipsychotic and antidepressant combinations are
prescribed, including cases in which the patient is suﬀering
their ﬁrst episode of psychotic major depression.
On the other hand in case C the precautionary suspen-
sion of olanzapine has not led to any clinical relapse though
the venlafaxine dosage has not been modiﬁed (it has now
been seven months since the patient’s discharge). In this case
we maintain the belief that sertraline may have caused the
onset of the patient’s psychotic symptoms.
Overall the association of venlafaxine and olanzapine
in psychotic major depression has demonstrated eﬃcacy, at
least as much as the most investigated combination, between
ﬂuoxetine and olanzapine.
Thedatastillneedtobeconﬁrmedthroughclinicaltrials;
however, there are diﬃculties in carrying out such studies
given that patients are often admitted when they are in a crit-
ical condition and, as such, unable to provide an adequate,
informed consent (e.g., patients who are in a catatonic state
or who are aﬀected by delusions of persecution).
The resulting mechanism from this combination of
venlafaxine and olanzapine remains, as yet, unclear. It could
be related to the speciﬁc mechanisms of olanzapine and
venlafaxine, and their pharmacodynamic interaction. Olan-
zapine is an antagonist and binds to serotonin (5HT2A/2C)
and dopamine (D1–4) receptors, and thus may combine
AD and AP eﬀects in a single compound. Furthermore,
olanzapine could increase the eﬀect of serotonin antagonism
in venlafaxine, likewise in ﬂuoxetine. However venlafaxine,
unlike ﬂuoxetine, has a dual mechanism of action including
a noradrenergic property, which may explain its more
rapid and eﬀective results in psychotic major depression
patients.
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